Hepadvax
Vaccine
Evidence outlook
No featureable registry evidence
The studies registered under this drug are withdrawn, terminated, not yet started, post-marketing only, or belong to other products, so none can represent its own clinical progression yet.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
Registered studies that name Chronic Hepatitis B were reviewed; none met the criteria for featured evidence.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Chronic Hepatitis B: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Hepadvax: this drug | Phase 1/2 | Vaccine | HBsAg (PreS) immunization | not yet graded | No reviewed efficacy summary in this indication | |
| Entecavir (Baraclude) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Protein / enzyme therapeutic | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lamivudine (Epivir-HBV) | ApprovedUS marketing discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | Reliable signal | Featured results are non-efficacy only in this race | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Reliable signal | NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants | |
| Besifovir Dipivoxil (Besivo) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | Partial signal | NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). | |
| Hepatitis B Immune Globulin (I.V.-Hepabig) | Phase 3 | Polyclonal Antibody (human Hepatitis B Immunoglobulin) | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3605 | Phase 3 | — | HBV core protein | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-008 | Phase 3 | Vaccine | Hepatitis B virus antigens (HBsAg + HBcAg) | not yet graded | No reviewed efficacy summary in this indication | |
| AHB-171 | Phase 2 | RNA / oligonucleotide | HBV RNA | not yet graded | No reviewed efficacy summary in this indication | |
| Daplusiran / Tomligisiran | Phase 2 | RNA / oligonucleotide | HBV RNA (X and S transcripts) | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Hepalatide | Phase 2 | Peptide | NTCP | not yet graded | No reviewed efficacy summary in this indication | |
| Libevitug (HH-003) | Phase 2 | Monoclonal antibody | HBV/HDV large envelope protein (PreS1 domain) | not yet graded | No reviewed efficacy summary in this indication | |
| Metacavir | Phase 2 | Small molecule | HBV reverse transcriptase (nucleoside analog) | not yet graded | No reviewed efficacy summary in this indication | |
| REP 2139-Mg | Phase 2 | — | HBsAg release (nucleic acid polymer) | not yet graded | No reviewed efficacy summary in this indication | |
| T101 | Phase 2 | Biologic (subtype unspecified) | HBV core, polymerase and envelope antigens | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3810 | Phase 2 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| CRMA-1001 | Phase 1/2 | Gene therapy / editing | HBV genome (cccDNA and integrated DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LW231 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| PA1010 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3038 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ACT201 | Phase 1 | RNA / oligonucleotide | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| CB06-036 | Phase 1 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| DA-2803 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Entecavir (Cavir) | Phase 1(overall) | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| HECN30227 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SA1211 | Phase 1 | RNA / oligonucleotide | Hepatitis B virus RNA (dual-target siRNA) | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-028 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Adefovir Dipivoxil (Hepsera) | Discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Telbivudine (Tyzeka) | Discontinued | — | HBV polymerase (reverse transcriptase) | Partial signal | NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Hepadvax to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.